ClinicalTrials.gg
CompletedNCT05305599NormaliZEDUpdated May 14, 2024

Different Doses of ZED1227 vs. Placebo in NAFLD

A Phase 2 interventional study of ZED1227 and Placebo in NAFLD and Liver Fibrosis, sponsored by Dr. Falk Pharma GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Dr. Falk Pharma GmbH · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany — 14 open to participants now, 21 under way, 8 of them phase 3. Non-alcoholic Fatty Liver Disease · Germany.

Enrollment
38th of 75
186 · median 186
Started
2022
with 3 others
Phase 2
28 of 89
none open now
Registered
72nd of 89
by date

Among the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, this one is the 38th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2022, is one of 28 in phase 2, and was the 72nd registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

14 of the 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Non-alcoholic Fatty Liver Disease with a site in Germany, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 20, 50, or 100 mg ZED1227 vs. placebo for the treatment of patients with NAFLD with fibrosis.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has provided signed
  • Is a male or female ≥ 18 and \< 75 years of age
  • Has diagnosed NAFLD
  • Has diagnosed significant fibrosis (stages 2 or 3)

Exclusion criteria

Exclusion Criteria:

  • Has a history of significant alcohol consumption (an average of > 20 g/d in females and > 30 g/d in males)
  • Has a history or presence of any other significant concomitant liver diseases
  • Has diagnosed type 1 diabetes mellitus (T1DM)
  • Has presence of cirrhosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    ZED1227 (low dose) 10 mg

    Drug: ZED1227

  • Experimental
    ZED1227 (middle dose) 25 mg

    Drug: ZED1227

  • Experimental
    ZED1227 (high dose) 50 mg

    Drug: ZED1227

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Relative change of PRO-C3 levels

    Relative change (%) of serum levels of PRO-C3 between baseline and the EOT.

    Time frame: 12 weeks

Secondary outcomes

  1. Incidence of adverse events

    Incidence of treatment-emergent adverse events.

    Time frame: from baseline to 16 weeks

07

Study locations

1 site
  • Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz
    Mainz, Rheinland-Pfalz 55131, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jun 2023, 13 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 13 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 31, 2022
StartActual
Apr 19, 2022
Primary completionActual
Jun 7, 2023
CompletionActual
Jul 5, 2023
Last update
May 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05305599
Responsible party
Sponsor
First posted
Mar 31, 2022
Start date
Apr 19, 2022
Primary completion
Jun 7, 2023
Completion
Jul 5, 2023
Last update
May 14, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZED1227

Start the discussion